NCT07344610 Effects of Short-term Intensive Statin Therapy on Lipid Levels
| NCT ID | NCT07344610 |
| Status | Recruiting |
| Phase | — |
| Sponsor | General Hospital of Shenyang Military Region |
| Condition | Ischemic Stroke |
| Study Type | OBSERVATIONAL |
| Enrollment | 800 participants |
| Start Date | 2026-01-08 |
| Primary Completion | 2026-12-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 800 participants in total. It began in 2026-01-08 with a primary completion date of 2026-12-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Acute cerebral infarction (ACI), often linked to arterial stenosis, is a major cause of death and disability. Statins are cornerstone therapies for secondary prevention, effectively lowering LDL-C and stabilizing plaques. However, patient response to intensive statin therapy varies significantly. This prospective study aims to analyze the short-term lipid-lowering effects and influencing factors of such therapy in ACI patients with stenosis, to guide personalized treatment and improve outcomes.
Eligibility Criteria
Inclusion Criteria: * Age ≥ 18 years; * Diagnosis of ischemic stroke (within 14 days of onset) confirmed by cranial CT/MRI; or imaging-confirmed intracranial/extracranial atherosclerotic stenosis (stenosis rate ≥ 50%); * Intensive statin therapy (e.g., atorvastatin 40-80 mg/day or rosuvastatin 20 mg/day) initiated within 24 hours of admission, with a planned continuous application for at least one week; * Signed informed consent form. Exclusion Criteria: * Use of statin therapy within 1 week prior to admission; * Receiving other lipid-lowering treatments; * Presence of other serious comorbidities (e.g., malignant tumors, end-stage heart failure) with an expected survival of \<1 year; * Pregnant or lactating women; * Participation in other drug clinical trials within 3 months; * Other conditions deemed unsuitable by the investigator.
Frequently Asked Questions
Who can join the NCT07344610 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Ischemic Stroke. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07344610 currently recruiting?
Yes, NCT07344610 is actively recruiting participants. Visit ClinicalTrials.gov or contact General Hospital of Shenyang Military Region to inquire about joining.
Where is the NCT07344610 trial being conducted?
This trial is being conducted at Shenyang, China.
Who is sponsoring the NCT07344610 clinical trial?
NCT07344610 is sponsored by General Hospital of Shenyang Military Region. The trial plans to enroll 800 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.